Sparking innovation at a Big Pharma with a 150-year history can be difficult, so sometimes it takes some outside perspective to get the ball rolling. That’s where Leaps by Bayer comes in.
Bayer’s venture arm has invested more than $1.5 billion from the balance sheet in the past six years to make bets on disruptive technologies.
Image: Jürgen Eckhardt, M.D., is the head of Leaps by Bayer, the Big Pharma’s venture investing arm. (Bayer)
{iframe}https://www.fiercebiotech.com/biotech/biopharma-vc-world-what-does-it-mean-to-take-a-leap-interview-head-leaps-by-bayer{/iframe}